Framingham Pharma

Framingham Pharma is a biotechnology company focused on the development of advanced drug delivery systems for the oral administration of biologics and other complex therapeutics. The company utilizes a proprietary platform, originated from research at MIT and Brigham and Women's Hospital, to enable the systemic absorption of molecules that are typically degraded in the digestive tract. By converting injectable therapies into oral formats, Framingham Pharma aims to improve patient compliance and therapeutic outcomes across a range of chronic diseases. Their current efforts are centered on pre-clinical validation of their technology for insulin and various monoclonal antibodies. The company's approach involves specialized formulations or devices that protect the drug cargo and facilitate its transport across the intestinal barrier. Framingham Pharma represents a significant effort to bridge the gap between high-potency biologics and the convenience of oral dosing.